Clinical Trial Update: A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the immune response and safety of an RSV vaccine given alone and with an influenza vaccine in adults aged 60 years and older; results h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• Influenza vaccine (influenza vaccine)
• RSV vaccine (respiratory syncytial virus vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 3 | Status: COMPLETED | Results posted: 2022-10-18